Sean Flynn Sells 15,000 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $45.64, for a total transaction of $684,600.00. Following the sale, the insider directly owned 1,647 shares in the company, valued at approximately $75,169.08. This trade represents a 90.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vericel Stock Up 1.5%

VCEL opened at $45.15 on Thursday. The firm has a 50-day moving average price of $36.69 and a 200-day moving average price of $35.95. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 107.50 and a beta of 1.06. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $46.62.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $68.43 million during the quarter, compared to analyst estimates of $63.68 million. Vericel had a net margin of 7.35% and a return on equity of 6.41%. Vericel’s revenue was up 30.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) EPS. On average, sell-side analysts expect that Vericel Corporation will post 0.49 earnings per share for the current fiscal year.

Institutional Trading of Vericel

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Vericel in the 1st quarter worth approximately $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Vericel by 6.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock valued at $1,403,000 after purchasing an additional 1,847 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Vericel by 13.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 44,333 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Vericel by 9.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock worth $5,490,000 after purchasing an additional 10,191 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Vericel by 5.1% in the second quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after purchasing an additional 13,422 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Truist Financial lowered their price objective on Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Weiss Ratings upgraded Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Wall Street Zen cut Vericel from a “buy” rating to a “hold” rating in a report on Sunday, June 14th. HC Wainwright reiterated a “buy” rating and set a $64.00 price target on shares of Vericel in a research report on Friday, May 8th. Finally, Leerink Partners reissued an “outperform” rating and set a $46.00 price objective on shares of Vericel in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $52.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.